Animal experiments - An essential component for the development of liposomal anticancer agents

Journal of Liposome Research

Volumn 13, Issue 1, 2003, Pages 9-15

  Fichtner, Iduna ^a   Reszka, Regina ^a   Arndt, Dieter ^a   Zeisig, Reiner ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Carboplatin; Cytostatics; Liposomes; Mouse; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DAUNORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; LIPOSOME; LOMUSTINE; METHOTREXATE; MITOXANTRONE; OCTADECYL (N,N DIMETHYLPIPERIDINIO 4 YL) PHOSPHATE; PACLITAXEL; PHOSPHOLIPID; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; ENCAPSULATION; HUMAN; HUMAN CELL; LEUKOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANIMALS, LABORATORY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBOPLATIN; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; FEMALE; LIPOSOMES; MICE; TAMOXIFEN;

EID: 0037237143     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.1081/LPR-120017483     Document Type: Conference Paper

References (9)

1. Fichtner I, Reszka R, Becker M, Lemm M, Richter J, Berger I, Rudolph M. Stimulation of hematopoiesis by carboplatin-liposomes. J Liposome Res 1994; 4(1):43-69.
2. Fichtner I, Reszka R, Goan S-R, Naundorf N, Hentschel M. Pharmacological effects of carboplatin-liposomes (CPL) in mice: a review of present knowledge. J Liposome Res 1995; 5(1):75-89.
3. Fichtner I, Reszka R, Goan S-R, Naundorf H. Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulation of hematopoiesis. Med Oncol 1994; 11(3-4):111-119.
4. Reszka R, Fichtner I, Goan S-R, Rudolph M, Winter R. Encapsulation of the transition metal compounds carboplatin (CP) and lobaplatin (LP) in different types of liposomes and their physico-chemical, biochemical and biological characterization. In: Trautwein AX, ed. Bioorganic Chemistry: Transition Metals and Their Coordination Chemistry. Weinheim, Germany: Wiley-VCH, 1997; 145-166.
5. Lykkesfeldt AE. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 1996; 35(Suppl 5):9-14.
6. Jordan VC. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 1998; 90(13):967-971.
7. Hilgard P, Klenner T, Stekar J, Unger C. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 1993; 32(2):90-95.
8. Fichtner I, Zeisig R, Naundorf H, Jungmann S, Arndt D, Asongwe G. Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Res Treat 1994; 32(3):269-279.
9. Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 1997; 33(3):442-446.